Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_assertion type Assertion NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_head.
- NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_assertion description "[The high incidence of CRF(1) or CRF(2) receptors in selected human tumors suggests that unlabeled CRF agonists may be evaluated as inhibitors of tumor cell proliferation in cancer therapy, and radiolabeled CRF analogs may be used for cancer diagnosis and/or radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_provenance.
- NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_assertion evidence source_evidence_literature NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_provenance.
- NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_assertion SIO_000772 12843181 NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_provenance.
- NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_assertion wasDerivedFrom befree-20150227 NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_provenance.
- NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_assertion wasGeneratedBy ECO_0000203 NP325921.RAdxFcKBnezKHezb6-LJd1XnppRUKlopwPM5tOTBew7Q0130_provenance.